<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-5945-3-3.anc" start="4991" end="4997" sStart="4849" offset="142" sid="r11.severe.j.0389" wn="1" wnkey="severe%5:00:00:intense:00" annotator="anfahmy" text="Histological scoring was made with a 5-point scoring system graded from 0 to 4 (0 = normal, 1 = slight, 2 - moderate, 3 = severe, 4 = very severe) based on criteria noted below after examination of four consecutive high-power fields." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-5945-3-3.anc" start="5008" end="5014" sStart="null" offset="159" sid="r11.severe.j.0086" wn="1" wnkey="severe%5:00:00:intense:00" annotator="anfahmy" text="Histological scoring was made with a 5-point scoring system graded from 0 to 4 (0 = normal, 1 = slight, 2 - moderate, 3 = severe, 4 = very severe) based on criteria noted below after examination of four consecutive high-power fields." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-5945-3-3.anc" start="5008" end="5014" sStart="null" offset="159" sid="r11.severe.j.0086" wn="6" wnkey="severe%5:00:01:bad:00" annotator="adelpriore" text="Histological scoring was made with a 5-point scoring system graded from 0 to 4 (0 = normal, 1 = slight, 2 - moderate, 3 = severe, 4 = very severe) based on criteria noted below after examination of four consecutive high-power fields." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-5945-3-3.anc" start="8494" end="8500" sStart="null" offset="13" sid="r9.normal.j.0439" wn="3" wnkey="normal%3:00:03::" annotator="cgozo" text="CBC remained normal (7." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-5945-3-3.anc" start="2055" end="2061" sStart="null" offset="185" sid="r9.level.n.0994" wn="1" wnkey="level%1:07:00::" annotator="anfahmy" text="IL-12, a product of Langerhans cells and skin monocytes plays a pivotal role in T-cell activation that leads to formation of the psoriatic plaque [ 22 ] . IL-12 levels are also significantly raised in patients with Graves' hyperthyroidism and are reduced following treatment with propylthiouracil [ 23 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-5945-3-3.anc" start="6940" end="6944" sStart="null" offset="33" sid="r11.dark.j.0451" wn="1" wnkey="dark%3:00:01::" annotator="vebatchelder" text="DAB was applied in the dark (10 min), the slides were washed in distilled water (5 min), counterstained with hematoxylin, washed with tap water, dehydrated and mounted." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-5945-3-3.anc" start="3862" end="3867" sStart="null" offset="25" sid="r10.board.n.0835" wn="1" wnkey="board%1:14:00::" annotator="cgozo" text="The Institutional Review Board of the University of California, Irvine, approved the study." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-5945-3-3.anc" start="8042" end="8048" sStart="null" offset="0" sid="null" wn="2" wnkey="become%2:42:01::" annotator="veweser" text="Clinical improvement &lt;b&gt;became&lt;/b&gt; apparent about three weeks after therapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-5945-3-3.anc" start="8042" end="8048" sStart="null" offset="0" sid="null" wn="1" wnkey="become%2:30:00::" annotator="tofox" text="Clinical improvement &lt;b&gt;became&lt;/b&gt; apparent about three weeks after therapy." />
  </sentences>
</list>